One of the most popular electronic health records software systems used by hospitals, Epic Systems, can delete records or require cumbersome workarounds when clocks are set back for an hour, prompting many hospitals to opt for paper records for part of the night shift.
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, Congress has received nearly $79 million from 68 pharma PACs, run by employees of companies that make drugs treating everything from cancer to erectile dysfunction.
A new Kaiser Health News database tracks campaign donations from drugmakers over the past 10 years.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
Researchers at the University of Southern California analyzed millions of prescriptions and concluded that close to a quarter paid copays that exceeded the cost of the drugs.
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
Una nueva investigación ha vinculado a los PPI, con graves efectos secundarios, incluyendo enfermedad renal crónica, y demandas presentadas recientemente alegan que los que producen la droga deberían haber sabido sobre sus daños potenciales.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
The numbers show that President Trump’s choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.